Characterization and prediction of positional 4-hydroxyproline and sulfotyrosine, two post-translational modifications that can occur at substantial levels in CHO cells-expressed biotherapeutics. Issue 7 (3rd October 2019)

• Record Type: Journal Article
• Authors: Tyshchuk, Oksana; Gstöttner, Christoph; Funk, Dennis; Nicolardi, Simone; Frost, Stefan; Klostermann, Stefan; Becker, Tim; Jolkver, Elena; Schumacher, Felix; Koller, Claudia Ferrara; Völger, Hans Rainer; Wuhrer, Manfred; Bulau, Patrick; Mølhøj, Michael
• Is Part Of: MAbs. Volume 11:Issue 7(2019)
• Page Start: 1219
• Page End: 1232
• Publication Date: 2019-10-03
• Subjects: Biotherapeutics -- fab purification -- MALDI-ISD FT-ICR -- hydroxyproline -- mass spectrometry -- PTM -- post-translational modification -- sulfotyrosine; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2019.1635865
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: Biotherapeutics may contain a multitude of different post-translational modifications (PTMs) that need to be assessed and possibly monitored and controlled to ensure reproducible product quality. During early development of biotherapeutics, unexpected PTMs might be prevented by in silico identification and characterization together with further molecular engineering. Mass determinations of a human IgG1 (mAb1) and a bispecific IgG-ligand fusion protein (BsAbA) demonstrated the presence of unusual PTMs resulting in major +80 Da, and +16/+32 Da chain variants, respectively. For mAb1, analytical cation exchange chromatography demonstrated the presence of an acidic peak accounting for 20%. A + 79.957 Da modification was localized within the light chain complementarity-determining region-2 and identified as a sulfation based on accurate mass, isotopic distribution, and a complete neutral loss reaction upon collision-induced dissociation. Top-down ultrahigh resolution MALDI-ISD FT-ICR MS of modified and unmodified Fabs allowed the allocation of the sulfation to a specific Tyr residue. An aspartate in amino-terminal position-3 relative to the affected Tyr was found to play a key role in determining the sulfation. For BsAbA, a + 15.995 Da modification was observed and localized to three specific Pro residues explaining the +16 Da chain A, and +16 Da and +32 Da chain B variants. The BsAbA modifications were verified as 4-hydroxyproline and not 3-hydroxyproline in a tryptic peptide map via co-chromatography with synthetic peptides containing the two isomeric forms. Finally, our approach for an alert system based on in-house in silico predictors is presented. This system is designed to prevent these PTMs by molecular design and engineering during early biotherapeutic development.